The Peptide Split: How GLP-1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewritin Medicine While BPC-157, TB-500, MOTS-c, and the Wellness Grift Borro Their Halo

MAY 08, 2026 • PAID

1

Quick Links: Knowledge Base, Podcast, and Social

Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech

Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive includi subscriber-only episodes. Listen on Apple Podcasts, Spotify, or browse all episo the Substack Podcast page.

For paid subscribers — your subscription unlocks the entire research archive (5 deep-dives), every paid podcast episode, and full search inside the Knowledge Ba listen to paid episodes in Apple or Spotify, link your Substack subscription via t show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

For free subscribers — free posts and free podcast episodes are always public or Apple/Spotify and Substack. Upgrade any time at onhealthcare.tech/subscribe to access the paid archive and paid episodes.

Follow on Social — X · YouTube · TikTok · Instagram

Video Preview



🎧 Podcast

0:00 -

Table of Contents

7. Section three: metabolic peptides are collapsing disease categories
8. Section four: peptides as oncology delivery systems
9. Section five: rare disease peptides and the precision side of the platform
10. Section six: the wellness peptide market is borrowing legitimacy from real d development
11. Section seven: what is conclusive, what is promising, and what is still noise
12. Section eight: the real breakthrough is engineered signaling biology, not "peptides"

Abstract

- Peptides are running two simultaneous revolutions and almost nobody is tal about them as separate stories.
- Real revolution: GLP-1 and GIP/GLP-1 agonism is now backed by hard outc data across cardiovascular events (SELECT, 20% MACE reduction), kidney d (FLOW, 24% reduction in major kidney outcomes), heart failure with preser ejection fraction plus obesity (SUMMIT, 38% reduction in worsening HF eve obstructive sleep apnea (SURMOUNT-OSA), and steatohepatitis (ESSENCE, 62.9% MASH resolution vs 34.3% placebo). Peptide radioligands like Lu-177 dotatate (NETTER-1, NETTER-2) and Lu-177 PSMA-617 (VISION, PSMAfo PSMAddition) are turning small targeting peptides into precision oncology delivery vehicles. CNP analogues (vosoritide) and PTH prodrugs (palopegteriparatide) are correcting specific developmental and endocrine d Peptide cancer vaccines targeting clean antigens like mutant KRAS (ELI-002 AMPLIFY-201) and the DNAJB1-PRKACA fusion in fibrolamellar carcinom producing credible immune and clinical signals in MRD settings.
- Wellness grift running in parallel: BPC-157, TB-500, MOTS-c, Semax, Epita DSIP, KPV, CJC-1295, ipamorelin, AOD-9604, and friends are sold by longe clinics and "research use only" mail-order vendors with claims far ahead of human RCT. FDA classifies most of these as Category 2 (substances with saf concerns) for 503A compounding. DOJ has prosecuted at least one major

compounder. WADA has banned several. Zero of these have a published larg scale, randomized, placebo-controlled human trial behind them.

- Major disappointments in the legit pipeline that the press has mostly underplayed: oral semaglutide failed both phase 3 Alzheimer's trials (EVOK EVOKE+), exenatide failed phase 3 in Parkinson's (Exenatide-PD3), CagriSe missed its 25% weight loss target and lost a head-to-head non-inferiority tes against tirzepatide (REDEFINE 4), and efruxifermin missed its primary end in compensated MASH cirrhosis at week 36.
- Misreported as a problem when it isn't: GLP-1 suicidality. FDA's 2026 revie found no increased risk and asked sponsors to remove the warning language
- Misreported as a solution when it isn't yet: Stanford's BRP peptide ("natura Ozempic") is mouse and minipig data, no humans.

What this essay argues:

- The real story is not "peptides." It is engineered signaling biology, which is mature enough to power generational therapeutic categories.
- The wellness peptide market is borrowing the halo of these drugs and the regulatory enforcement gap is widening.
- Investors, operators, and clinicians who treat "peptide" as a single category going to make bad decisions in both directions, missing real platform opportunities and tolerating products that do not have the evidence to justi their claims.

Section one: peptides are not supplements, they are programmable physiology

There is a vocabulary problem at the heart of the peptide conversation and it is real damage. The word peptide covers semaglutide, which has multi-organ outc data across hundreds of thousands of patient-years of exposure, and it also cover some sketchy vial labeled "BPC-157, research use only, not for human consumpt

sold through a mail-order site that takes crypto. Same word. Wildly different thi
A peptide is just a short chain of amino acids, usually defined as somewhere und
fifty residues, longer than that and you are calling it a protein. So the category
includes everything from insulin (which is technically two short chains) through
1 agonists, somatostatin analogues, calcitonin gene-related peptide blockers,
gonadorelin analogues, and the entire pipeline of next-gen incretin agonists and
peptide vaccines. The point is, "peptide" tells you almost nothing about the
molecule's pharmacology, evidence base, regulatory status, or risk profile. It just
you the chemistry class.

The right way to think about peptides is as programmable signaling. Most pepti
drugs are doing one of a few things: agonizing or antagonizing a receptor that ev
to bind an endogenous peptide hormone (GLP-1, GIP, glucagon, amylin, somatos
PTH, ANP, CNP, the melanocortins), serving as a homing ligand to deliver a payl
(Lu-177 dotatate, Lu-177 PSMA-617, melflufen), presenting a tumor antigen to t
immune system (neoantigen vaccines, mutant KRAS vaccines, fusion antigen vac
or modulating immunity directly (some antimicrobial peptides, some immune
checkpoint adjacent work). What unites the legitimate side of the field is that th
exploits a specific, characterized pathway with a specific, measurable target
engagement story. Receptor binding kinetics, downstream signaling,
pharmacokinetics, dose response, the whole boring drug development apparatus
What unites the wellness side of the field is that none of that is true. The mecha
is hand-waved at, the dosing is whatever the clinic feels like, the manufacturing
is opaque, and the evidence base is rodent studies plus testimonials.

The reason this matters now and not five years ago is that the credible side of pe
medicine has reached escape velocity. GLP-1 agonism has the cleanest
cardiometabolic outcomes data of any drug class developed in the last twenty ye
peptide radioligands are eating into solid tumor categories that were considered
locked, peptide cancer vaccines are showing real immune readouts in pancreatic
cancer and rare hepatocellular variants, and the manufacturing economics for
peptides have improved enough that the field is starting to compete with small
molecules on cost. Meanwhile, the wellness peptide market is also at escape velo

just on TikTok instead of in NEJM. Both things are happening at once, both are the same word, and most healthcare media coverage flattens them into a single s

Section two: GLP-1s proved peptide drugs can change hard outcomes, not just biomarkers

← Previous